Circle Pharma and Verismo feature in coveted sessions.
ApexOnco Front Page
Recent articles
The Swiss group shells out $2bn for Synnovation’s mutation-selective PI3Kα inhibitor.
Keynote-905 finds a 50% reduction in the risk of death in (neo)adjuvant muscle-invasive bladder cancer.
But it will be up to regulators to decide if giredestrant has done enough for an all-comers label.
Alongside full PIK3CA wild-type data, Celcuity sets the bar for gedatolisib's PIK3CA-mutant readout.
Artios, Synnovation and Novartis show mere glimmers of activity.
Boehringer’s Hernexeos and Bayer’s sevabertinib look similar in first-line HER2-mutant NSCLC.
Imfinzi and sasanlimab look nearly identical, but it’s a different story for Roche’s Tecentriq.
